A study of NHS patients using new obesity drugs found a significant decrease in sick days taken, dropping from 517 to 334 days within three months. After six months, 77% of patients reported taking no sick leave, an increase from 63% before treatment. The findings suggest that wider access to these weight-loss injections could result in notable economic benefits by improving workforce productivity and reducing healthcare costs, potentially saving the taxpayer £5 billion annually.
The latest generation of obesity drugs significantly reduced sick leave, with the number of sick days taken falling by a third within three months of starting treatment.
77% of patients reported taking no sick leave after six months of treatment, highlighting the positive economic impact of obesity medication on workforce participation.
Collection
[
|
...
]